menu
    • menu
    [{"orgOrder":0,"company":"Nicox Ophthalmics","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Cetirizine","moa":"Histamine H1 receptor||Histamine H1 receptor (H1R)","graph1":"Undisclosed","graph2":"Phase III","graph3":"Nicox Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nicox Ophthalmics \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Nicox Ophthalmics \/ Ora, Inc"},{"orgOrder":0,"company":"Aciex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Cetirizine","moa":"Histamine H1 receptor||Histamine H1 receptor (H1R)","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aciex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aciex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aciex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aciex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Cetirizine","moa":"Histamine H1 receptor||Histamine H1 receptor (H1R)","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aciex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aciex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aciex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aciex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Cetirizine","moa":"Histamine H1 receptor||Histamine H1 receptor (H1R)","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aciex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aciex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aciex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aciex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Cetirizine","moa":"Histamine H1 receptor||Histamine H1 receptor (H1R)","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aciex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aciex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aciex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aciex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Cetirizine","moa":"Histamine H1 receptor||Histamine H1 receptor (H1R)","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aciex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aciex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aciex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aciex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Cetirizine","moa":"Histamine H1 receptor||Histamine H1 receptor (H1R)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Aciex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aciex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aciex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"McNeil AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Cetirizine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"McNeil AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"McNeil AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"McNeil AB \/ Undisclosed"},{"orgOrder":0,"company":"California Allergy and Asthma Medical Group","sponsor":"McNeil Consumer Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Cetirizine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"California Allergy and Asthma Medical Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"California Allergy and Asthma Medical Group \/ McNeil Consumer Health","highestDevelopmentStatusID":"11","companyTruncated":"California Allergy and Asthma Medical Group \/ McNeil Consumer Health"},{"orgOrder":0,"company":"Queen's University","sponsor":"Biogenics Research Chamber, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Cetirizine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Queen's University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Queen's University \/ Biogenics Research Chamber, LLC","highestDevelopmentStatusID":"11","companyTruncated":"Queen's University \/ Biogenics Research Chamber, LLC"},{"orgOrder":0,"company":"Providence Health & Services","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Cetirizine","moa":"Histamine H1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Providence Health & Services","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Providence Health & Services \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"Providence Health & Services \/ Genentech"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Cetirizine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Johnson & Johnson \/ Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson \/ Pfizer Inc"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Cetirizine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"TerSera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Cetirizine","moa":"Histamine H1 receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"TerSera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TerSera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TerSera Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Zyrtec Syrup

    Menu

    Zyrtec Syrup

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TerSera Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            TerSera Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetirizine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2 Study IV QUZYTTIRâ„¢ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine

                            Details : Cetirizine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 06, 2019

                            Lead Product(s) : Cetirizine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Providence Health & Services

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Providence Health & Services

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetirizine

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Genentech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocre...

                            Details : Cetirizine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Multiple Sclerosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 25, 2019

                            Lead Product(s) : Cetirizine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Genentech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Johnson & Johnson

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Johnson & Johnson

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetirizine

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cetirizine Chewable Bioequivalence and Food Effect Study

                            Details : Cetirizine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hypersensitivity.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 11, 2018

                            Lead Product(s) : Cetirizine

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Johnson & Johnson

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Johnson & Johnson

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetirizine

                            Therapeutic Area : Immunology

                            Study Phase : Phase IV

                            Sponsor : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of...

                            Details : Cetirizine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Rhinitis, Allergic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 13, 2016

                            Lead Product(s) : Cetirizine

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase IV

                            Sponsor : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nicox Ophthalmics

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Nicox Ophthalmics

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetirizine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Sponsor : Ora, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution

                            Details : AC-170 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 29, 2016

                            Lead Product(s) : Cetirizine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Sponsor : Ora, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Queen's University

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Queen's University

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetirizine

                            Therapeutic Area : Immunology

                            Study Phase : Phase IV

                            Sponsor : Biogenics Research Chamber, LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparability and Standardization of Controlled Allergen Challenge Facilities

                            Details : Cetirizine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Rhinitis, Allergic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 07, 2015

                            Lead Product(s) : Cetirizine

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase IV

                            Sponsor : Biogenics Research Chamber, LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Aciex Therapeutics

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Aciex Therapeutics

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetirizine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Multi-Center Study Evaluating the Safety of AC-170 0.24%

                            Details : AC-170 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Conjunctivitis, Allergic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 07, 2014

                            Lead Product(s) : Cetirizine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Aciex Therapeutics

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Aciex Therapeutics

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetirizine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

                            Details : AC-170 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Conjunctivitis, Allergic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 19, 2013

                            Lead Product(s) : Cetirizine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            California Allergy and Asthma Medical Group

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            California Allergy and Asthma Medical Group

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetirizine

                            Therapeutic Area : Immunology

                            Study Phase : Phase IV

                            Sponsor : McNeil Consumer Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Bronchodilation Effects of Cetirizine

                            Details : Cetirizine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Rhinitis, Allergic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 01, 2013

                            Lead Product(s) : Cetirizine

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase IV

                            Sponsor : McNeil Consumer Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Aciex Therapeutics

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Aciex Therapeutics

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetirizine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

                            Details : AC-170 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Conjunctivitis, Allergic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 14, 2012

                            Lead Product(s) : Cetirizine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth